Biohit (BIOBV) investor relations material

Executive summary

• Revenue for January–June 2026 rose 5.7% year-over-year to EUR 7.8 million, with operating profit up 28.6% to EUR 1.5 million and an improved margin of 19.4%.

• GastroPanel product line saw sales increase by 90.1% year-over-year, driving profitability and international growth.

• International operations contributed 98.7% of total revenue, with notable expansion in Latin America and the UK.

• The Italian subsidiary was discontinued in favor of a distributor model, improving profitability despite lower sales.

Financial highlights

• Operative EBITDA reached EUR 1.7 million (21.9% of revenue), up from EUR 1.4 million (18.3%) year-over-year.

• Earnings per share increased to EUR 0.09 (undiluted), up 39.6% from the prior year.

• Profit for the period was EUR 1.3 million, up 39.7% year-over-year.

• Equity ratio improved to 78.9% from 74.1% a year earlier.

• Cash and cash equivalents at period end were EUR 1.6 million, down from EUR 3.9 million in the prior year.

Outlook and guidance

• 2026 revenue is expected to reach EUR 16.5–17.3 million, representing 5–10% growth over 2025, with an operating margin of at least 10%.

• Strategic targets for 2024–2028 include annual revenue growth of 15–20% and EBIT of at least 10% of revenue.